ArticleFrontiers in public health2024
Evaluating the epidemiology of vaginitis in a contemporary cohort: a population-based study.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Epidemiology, Diagnostics and Therapy of Vulvovaginal Fungal Infections.Pathogens (Basel, Switzerland) · 2026Review
- Effects of Antimicrobial Underwear on Vaginal Symptoms and Vaginal Microbiota: A Prospective Study.Journal of clinical medicine · 2026Article
- Associations between vaginal microecological status and high-risk human papillomavirus positivity in women from Eastern China: a retrospective cross-sectional study.Frontiers in medicine · 2026Article
- Could diet and body composition influence vaginitis treatment success? A clinical nutrition-based analysis.Frontiers in nutrition · 2026Article
- Aetiology of Vulvovaginal Candidiasis in Ecuador and In Vitro Antifungal Activity AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Methods: We conducted a population-based cohort study from March 2015 through March 2018 using the Alberta Precision Laboratories (APL) microbiology database. Calgary 2016 census data was used to calculate incidence rates (IR) and ratios (IRR) for cases and testing rates. Results: For testing and positivity, female sex, and younger age groups were associated with increased risk of BV, VVC, and TV infections. The annual mean population in 2016 was 1,411,660 individuals (50.3% female). A total of 40,259 cases/293,853 tests (13.7%) of BV, 32,894 cases/293,853 tests (11.2%) of VVC, and 2018 cases/342,986 tests (0.7%) of TV were identified. The overall IR for BV ranged from 0 to 609 cases per 10,000 person-years. The overall IR for VVC ranged from 0 to 445 per 10,000 person-years. The overall IR for TV ranged from 0 to 27 per 10,000 person-years. The highest age-specific testing positivity rate and IR rate for BV and VVC occurred in women aged 20-34 years and 20-34 years. For TV, female IR for BV, VVC, and TV remained stable during the study. Discussion: These unique regional data provide insight for the development of appropriate age-specific clinical testing criteria according to relative risk of acquisition of each vaginitis agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.